1 | INTRODUCTION
| Genetic complexity of Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that often results in memory loss and cognitive impairment. [1] [2] [3] [4] [5] [6] [7] [8] [9] The classical neuropathological hallmarks for AD include: (1) Aβ-amyloidcontaining neuritic plaques and (2) phosphorylated Tau-containing neurofibrillary tangles (NFTs). 2, 3, 10, 11 The clinical phase of AD is also marked significantly by synaptic loss, selective neuronal death, neurotransmitter loss and neuroinflammation. 1, 3, 4, 6, 8, 10, 11 At present, there are no disease-modifying treatments for this fatal illness. As of today, mutations in 3 genes: amyloid precursor protein (APP), presenilin (PS)1
and PS2, have all been linked to early onset of AD (EOAD), [12] [13] [14] [15] which only account for a very small number of AD cases. Extensive investigation of these mutations has helped to formulate the Aβ-amyloid hypothesis, 1, 5 positing that small Aβ-amyloid peptides (Aβ 40/ 42 ) underlie the pathogenesis of AD. This has led to many clinical trials that use approaches (inhibitors, antibodies, etc.) to target and to reduce the buildup of toxic Aβ-amyloid peptides. Unfortunately, the anti-amyloid-based treatments have all failed in clinical trials thus far. 16, 17 Similarly, intensive efforts have also been made to develop inhibitors to prevent aggregation of Tau-containing NFTs. However, these efforts have also failed in recent clinical trials. 18 Nevertheless, studies of these hereditary mutations in APP, PS1/2 have helped to gain a greater understanding of the molecular pathogenesis of AD.
One of the most important lessons we have learned from these failed clinical efforts is that the cause(s) for AD is far more complex than we originally anticipated. 11 For example, the incidence of late-onset AD (LOAD) accounts for the majority cases of AD and the cause(s) for LOAD is far from clear in comparison to that for EOAD. In 2009, apolipoprotein E (APOE), which plays an important role in lipid transport, Aβ trafficking, synaptic function, immune regulation and intracellular signaling, 19 was identified as an established risk factor for LOAD. 20 More recently, large-scale genome-wide association studies (GWAS) and a meta-analysis have identified significant associations between LOAD with SNPs in~20 additional loci includ- ing CLU, CR1, PICALM, BIN1, ABCA7, MS4A4, EPHA1, CD2AP, CD33,   INPP5D, MEF2C, HLA-DRB1/HLA-DRB5, NME8, ZCWPW1, PTK2B, SORL1, CELF1, SLC24A4/RIN3, FERMT2 and CASS4. [21] [22] [23] [24] [25] [26] Identification of these additional risk factors highlights the extraordinary genetic complexity of AD. Furthermore, BIN1 is significantly correlated with the amount of pTau-containing NFT pathology 33 and has been implicated in modulating Tau-associated neuronal toxicity. [33] [34] [35] The sortilin-related receptor 1 (SORL1) regulates intracellular trafficking and processing of APP. [36] [37] [38] [39] In the absence or reduced expression of SORL1, APP is released into late endosomal pathway, where it is subjected to both β-and γ-secretase cleavage, thus driving Aβ production. 40, 41 Mutations in SORL1 have been associated with both EOAD and LOAD. 42, 43 In addition, APOE and CLU (Clusterin) both influence Aβ-aggregation and receptor-mediated Aβ clearance by endocytosis. 19, 44, 45 Although each of these genes confers only an incremental risk to AD, together they may play a significant role in altering endocytic processes, such as internalization, endocytic trafficking and signaling, that ultimately contribute to molecular pathogenesis of LOAD. 46 
| Endocytic trafficking and amyloidogenic processing of APP
Neurons with the most extraordinary architecture have elaborate dendrites and axons, so it is not surprising that strong evidence has suggested that these early endocytic processes are dysregulated in AD [47] [48] [49] [50] and in AD cases of people with Down syndrome (DS). 51 For instance, amyloidogenic cleavage of APP to yield Aβ likely occurs predominantly in the intracellular compartments. [47] [48] [49] [50] 52, 53 Under normal conditions, the early endosome, marked by Rab5, is a major site of APP processing by β-secretase to yield the β-cleavage C-terminal fragment (β-CTFs), [54] [55] [56] [57] which is further processed in late endosomes or trans-Golgi network to give rise to Aβ. Therefore, APP metabolism that produces toxic β-CTFs and Aβ is intimately regulated by the endocytic pathways. [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] Dysregulation of Rab5 can thus profoundly impact APP processing and Aβ production. In AD, abnormal enlargement of Rab5-positive early endosomes is not only characteristic, it is early; it was observed in non-demented individuals who were diagnosed post-mortem as fulfilling the pathological diagnosis of sporadic AD. 47 Interestingly, endosomal pathology was detected in brain regions that were free of Aβ or pTau pathology, 58, 68 suggesting that early endosomal abnormalities precede not only the onset of dementia but also the emergence of plaques and tangles.
| Axonal toxicity of APP β-CTFs and pTau
Although neuronal toxicities by β-CTF or C99 have been observed for quite some time, [69] [70] [71] [72] little is known about the underlying cellular mechanism(s). Recent evidence has pointed to a strong adverse impact of β-CTF on synaptic plasticity and neuronal function. The effect appears to be independent of Aβ, but is intimately linked to early cellular pathology in AD. 49, 55, [72] [73] [74] [75] [76] [77] [78] [79] Tau and phosphorylated Tau in these AD neurons. 81 They further demonstrated that γ-secretase inhibition that resulted in accumulation of APP-β-CTF/α-CTF led to an increase in tau, while treatment with inhibitors of β-secretase decreased Tau. 81 Therefore, intracellular trafficking and processing of APP impacts tau proteostasis as well.
Because disruption of tau homeostasis has been implicated in disrupting axonal function, 18, 34, 35, [82] [83] [84] [85] [86] the link between β-CTF and Rab5 dysregulation, and between endosomal dysfunction and pTau thus warrants further investigation. RIN3, the Ras and Rab interactor 3, a stimulator and stabilizer for GTP-Rab5 87,88 identified in recent GWAS, 21, 23, 24 may fill an important gap linking β-CTF to Rab5 dysregulation in AD.
| Dysregulation of Rab5 in AD
Rab5 is a small GTPase that cycles between an inactivate GDP-bound form and an active GTP-bound form for its biological functions. [89] [90] [91] [92] [93] Activation of Rab5 requires guanine-nucleotide exchange factors (GEFs) such as RIN3. 89, 93 Inactivation of Rab5 is under the control of GTP-hydrolysis-activating proteins (GAPs) 94 due to a low intrinsic rate of GTP hydrolysis by Rab5 itself. It is under the dual control by both GEFs and GAPs, and Rab5 regulates early steps of endocytosis, ensuing endosomal membrane trafficking, sorting and endosomal fusion. Dysfunction of retromers has also been implicated in AD. 57, 120, 121 Retromer is a protein complex that mediates endosometo-Golgi transport. The levels of Vps35 and Vps26, 2 key retromer proteins, were significantly reduced in the entorhinal cortex of AD patients. 57, 120 Vps26 binds to a hexapeptide motif (FANSHY) in the cytoplasmic tail of the sorting receptor SorLA (aka SORL1 or LR11). 122, 123 SorLA is a neuronal sorting protein that directs trafficking of APP also from endosomes to the Golgi. 122, 123 It is thus conceivable that reduced levels of SorLA in conjunction with dysfunctional retromer would exacerbate the deficit of APP trafficking from endosomes to Golgi, resulting in accumulation of APP in endosomes. It is within the endosomal compartments enriched with proteolytic enzymes, APP is processed by β-secretase to drive the production of β-CTF and Aβ. 57, [121] [122] [123] In addition to Rab5-containing early endosomes, the recycling endosomal pathways mediated by Rab4/Rab11 that regulate intracellular sorting, trafficking and processing of APP have been found to be altered as well in AD. 124 Accumulation of APP β-CTF has been shown to impair a key neuronal-specific soma-to-axon transcytosis pathway. 125, 126 Using induced pluripotent stem cell-derived human neurons with familiar AD mutations in PS1 (presenilin 1) and APP, a recent study from Goldstein's laboratory has demonstrated that subcellular distribution and trafficking of APP was altered in these neurons 125 ; the level of APP was increased in the soma while APP in the axons was significantly reduced, a pattern closely reminiscent of the distribution of Rab11 in these neurons. 125 Furthermore, knocking down Rab11 induced a similar defect in soma-to-axon transcytosis of APP in isogenic control neurons. 125 These studies have demonstrated that Rab11 plays a key role in the neuronal soma-to-axon transcytosis and dysfunction of Rab11 may also contribute to the early phase of AD pathogenesis.
| Increased APP and its β-CTF leads to enlargement of Rab5+ early endosomes
One of the earliest neuronal pathologies of AD is endosomal dysfunction that was observed in AD patients prior to the deposition of any extracellular β-amyloid (Aβ). 60, 63, 127 In addition, patients with DS, who are known to develop AD pathology after the age of 40, also show these same endosomal abnormalities as early as 28 weeks of gestation. 110, 127 These findings suggest that neurons become compromised intracellularly well before any plaque formation or tau accumulation occurs in the brain. Endosomal alterations reported in these 2 neurological disorders include increased endocytosis and enlarged early endosomes that contain the early endosomal protein Rab5. 60, 63, 115, 128 Studies have also provided evidence that the cellular level of amyloid precursor protein (APP) is linked to Rab5-containing early endosomal abnormalities. . Therefore, consistent with studies from Nixon's group, 80 these studies have demonstrated a role played by APP β-CTFs in mediating cellular toxicity by accumulation of toxic APP products.
| APP/β-CTF acts through Rab5 to impair retrograde axonal trafficking of NGF leading to neuronal atrophy
NGF is a target-derived neurotrophic factor that acts through its sur- Importantly, we have demonstrated that axonal transport deficits and neuronal atrophy can be rescued through the expression of a dominant-negative Rab5 mutant, both in BFCN neurons as well as in a fly model of AD. 80 These studies have further confirmed the contribution of hyperactivated Rab5 to axonal transport deficits and neuronal atrophy in AD. [78] [79] [80] On the basis of our studies, we propose the following model to explain how NGF-TrkA signaling transport is impacted in the presence of APP β-CTF through increased activation of Rab5. In normal BFCNs (Figure 2A Recent GWAS have identified RIN3 as a risk factor for AD. RIN3, a guanidine nucleotide exchange factor (GEF) for selective members of the Rab5 family (Rab5, Rab21, Rab22, Rab24 and Rab31), 87, 88 functions as the stimulator and stabilizer for GTP-Rab5. 87 ,88 RIN3 has a Src homology 2 (SH2) domain, a proline-rich domain (PRD), a RIN-homology (RH) domain, a Vps9 (vacuolar protein sortingassociated protein 9) conserved in the catalytic domains of the Rab5
GEFs (Vps9p, Rabex-5, etc.) and a Ras-association (RA) domain ( Figure 3A) . 87 It is possible that increased activity of RIN3 is responsible for the increase in the level of GTP-Rab5, which results in early endosomal abnormalities and axonopathy, leading to neuronal degeneration in AD. However, it remains to be defined: (1) GEFs other than RIN3 also play a role in increased Rab5 activation in AD.
| APPL1
In addition to RIN3, APPL1 (AP, phosphotyrosine interacting with PH domain and leucine zipper 1), an Rab5 effector ( Figure 3B ), has been
shown to link APP β-CTF to Rab5 overactivation in AD and DS. 80 In endosomes. 80 Importantly, these endocytic defects in fibroblasts from DS were rescued by knocking down APPL1. Therefore, APPL1 represents an important adaptor that links APP β-CTF to hyperactivation of Rab5 and to endosomal dysfunction in AD and DS. However, this novel APPL1-dependent pathogenic pathway in AD will need to be further validated.
| Dysregulation of Rab5 in PD
In addition to AD, recent studies have also pointed to that Rab5-mediated endocytic functions are impacted in PD, for which α-synuclein aggregates, a major component of Lewy bodies and asso- Because expression of PICALM is much higher in endothelial cells than in neurons, 143 reduced levels of PICALM may, therefore, impair
Aβ clearance more than Aβ production in LOAD patients. Increased accumulation of extracellular Aβ will undoubtedly upset the Rab5 endocytic pathways in neurons to impact their well-being. 51 This may explain why a minor PICALM allele (rs3851179 SNP), associated with increased expression of PICALM, is protective against AD likely by increasing clearance of extracellular Aβ to reduce its toxicity on neurons. 27 On the other hand, although the pathogenic mechanism of BIN1 is presently unknown, one can speculate that elevated level of BIN1 in LOAD patients [33] [34] [35] 44 increases endocytosis and promotes Aβ production in neurons, 34 which in turn may induce activation of Rab5 to impair trafficking and signaling of neurotrophic factors. 51 
| CONCLUSION
AD is an extremely complex disease that involves many different cell types, factors and pathways. These different components may act independently or work in tandem to contribute AD pathogenesis. It has become increasingly clear that homeostasis of endocytic sorting, trafficking and signaling, which is critical for maintaining neuronal function, is disrupted in AD. Those AD risk factors discovered in GWAS that target the endocytic pathways may act alone or work in tandem to impair the normal function and process of the endocytic pathways. Delineating the interplays among these factors and pathways will not only enhance our understanding of the mechanisms responsible for neurodegeneration in AD and other diseases, but also will facilitate the discovery of novel target for developing treatment strategies for these disorders.
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